RxSight, Inc. (NASDAQ:RXST)
| Market Cap | $187.42M-56.8% |
| Revenue (ttm) | $121.83M-14.3% |
| Net Income | -$53.36M-49.3% |
| EPS | -$1.28-45.5% |
| Shares Out | 41.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 539,306 |
| Open | $4.61 |
| Previous Close | $4.61 |
| Day's Range | $4.45 - $4.74 |
| 52-Week Range | $4.11 - $13.22 |
| Beta | 1.19 |
| Analysts | Hold |
| Price Target | $6.06(+35.57%) |
| Earnings Date | Feb 24, 2027 |
About RXST
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
5 firms rating RXST in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 24, 2027Earnings report
$RXST stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RXST holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RXST's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RXST Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RXST patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RXST from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RXST
| IWMiShares Russell 2000 ETF | $4.78M |
| VTIVanguard Morningstar Total Stock Market ETF | $4.71M |
| VXFVanguard Extended Market ETF | $2.06M |
| IWNiShares Russell 2000 Value ETF | $1.79M |
| VTWOVanguard Russell 2000 ETF | $1.14M |
| SCHASchwab U.S. Small-Cap ETF | $896.35K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from RXST’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 25Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
